These results were validated in an internal cohort of patients with advanced NSCLC, treated with cisplatin/carboplatin (n = 32) or pembrolizumab (n = 43) as first line (Supplemental Table S2): in both chemotherapy or immunotherapy-treated patients, high TFEB and ABCA1 were associated with better PFS and OS, high ABCC1 with worse outcome (Supplemental Fig. S1A-B). This evidence concerns the gene TFEB and non-small cell lung carcinoma.